Actively Recruiting
Statin Combined with Amlodipine Treats Primary Aldosteronism
Led by Third Military Medical University · Updated on 2024-11-22
180
Participants Needed
1
Research Sites
107 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
The drug treatment for primary aldosteronism (PA) is limited and difficult to improve long-term cardiovascular outcomes. This study plans to enroll patients with primary aldosteronism and randomly divide into 3 groups: scheme 1: Statin combined with amlodipine besylate, scheme 2: Statin combined with Spironolactone and Amlodipine besylate. scheme 3: Amlodipine besylate combined with Spironolactone , to observe the changes in plasma aldosterone level, 24-hour urinary aldosterone, blood pressure, and long-term cardiovascular risk.
CONDITIONS
Official Title
Statin Combined with Amlodipine Treats Primary Aldosteronism
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Clinical diagnosis of primary aldosteronism
You will not qualify if you...
- Allergy to drugs in this study
- Pregnancy
- Severe liver and kidney dysfunction
- Mental illness
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
No. 10 Changjiang River Branch, Yuzhong District，Chongqing, China
Chongqing, Chongqing Municipality, China, 400042
Actively Recruiting
Research Team
S
sun fang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
3
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here